# Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy

**Authors:** Chia‐Hsuan Chang, Claire Watson, Diptendu Chatterjee, Jade Ward, Kieran Borgeat, Hannah Hodgkiss‐Geere, Joanna Dukes‐McEwan, Robert Hamilton, Melanie J. Hezzell

PMC · DOI: 10.1002/vetr.6014 · The Veterinary Record · 2025-12-06

## TL;DR

This study found that anti-desmoglein-2 autoantibodies are not reliable for diagnosing arrhythmogenic right ventricular cardiomyopathy in boxer dogs.

## Contribution

The study clarifies the limited diagnostic value of anti-DSG2 autoantibodies in ARVC for boxer dogs.

## Key findings

- Anti-DSG2 autoantibodies were detected in all but one healthy boxer dog.
- DSG2 levels were significantly lower in preclinical versus clinical ARVC dogs.
- DSG2 autoantibodies were present in both healthy and ARVC-affected dogs.

## Abstract

Evidence regarding the diagnostic utility of serum anti‐desmoglein‐2 (DSG2) autoantibodies for arrhythmogenic right ventricular cardiomyopathy (ARVC) in boxer dogs is conflicting.

Prospective standardised evaluation of apparently healthy boxer dogs for ARVC was performed at three referral centres, including blood pressure measurement, electrocardiography, echocardiography, haematology, biochemistry (including cardiac troponin I) and 24‐hour Holter monitoring. Additional dogs with a diagnosis of ARVC were retrospectively recruited. ARVC disease status was defined using cut‐offs of 20 or less (unaffected) and more than 300 (affected) ventricular premature complexes of right ventricular origin in 24 hours. The residual serum samples were stored at ‒80°C for analysis for anti‐DSG2 autoantibodies using ELISA techniques.

Forty boxer dogs were enrolled (11 healthy controls, 10 with preclinical ARVC and 19 with clinical ARVC). Serum anti‐DSG2 autoantibodies were detected in all dogs, bar one healthy dog. DSG2 differed significantly between groups (p = 0.031) and was significantly lower in dogs with preclinical versus clinical ARVC (p = 0.025).

Some data were collected retrospectively, and some dogs were receiving antiarrhythmic therapy.

Serum DSG2 autoantibodies can be present in boxer dogs with preclinical and clinical ARVC and apparently healthy controls.

## Linked entities

- **Proteins:** DSG2 (desmoglein 2)
- **Diseases:** arrhythmogenic right ventricular cardiomyopathy (MONDO:0016587)

## Full-text entities

- **Genes:** DSG2 (desmoglein 2) [NCBI Gene 490500]
- **Diseases:** ventricular premature complexes (MESH:D018879), ARVC (MESH:D019571)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023020/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13023020/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023020/full.md

---
Source: https://tomesphere.com/paper/PMC13023020